Abstract. In a previous study, one spliced transcript of human cytomegalovirus (HCMV), named UL21.5 was identified. UL21.5 has been found to be one of the viral transcripts packaged within HCMV particles. The UL21.5 mRNA is translated into a secreted glycoprotein, which is a viral chemokine decoy receptor specifically interacting with regulated upon activation normal T cell expressed and secreted (RANTES). In the present study, four novel low-abundance 3'-coterminal spliced transcripts were identified to be transcribed from the UL21.5 gene region of a low-passage HCMV strain during the late infection phase by cDNA library screening, northern blot hybridization, reverse transcription polymerase chain reaction (RT-PCR) and rapid amplification of cDNA ends (RACE)-PCR. Three splicing donor and three splicing acceptor sites found in the UL21.5 gene region were validated to be functional in an in vitro expression system. In addition, the determinant regulatory region that is necessary for the splice donor site at nucleotide (nt) 25533 was located in a 9-bp sequence around the site; the regulatory regions for the splice acceptor sites at nt 26597 and nt 26633 were located in a 20-bp sequence upstream of the site at nt 26597 and in a 10-bp sequence from nt 26641 to nt 26650 downstream of the site at nt 26633, respectively.
Introduction
Human cytomegalovirus (HCMV) is the prototype member of the betaherpesvirus family (1, 2) . HCMV infection is generally asymptomatic in healthy individuals; however, it can cause severe disease in immunocompromised patients, such as AIDS and transplant patients (3) . Congenital HCMV infection in newborns may cause multiple malformations and diseases, including jaundice (associated with hepatitis), mental retardation, blindness and deafness, involving multiple systems (4) . HCMV contains a 240-kb double-stranded DNA genome which encodes over 165 open reading frames (ORFs) and several microRNAs (miRNAs) (5) (6) (7) (8) (9) (10) . The HCMV genome has three expression phases, i.e., immediate-early (IE), early (E) and late (L) (2) .
To date, fewer than 100 predicted genes and partial gene segments have been extensively characterized with respect to their expression patterns, transcript structures and transcription characteristics (11) . Some of these genes produce multiple gene products due to the alternative splicing of pre-messenger RNA (pre-mRNA) (12, 13) . The majority of the alterna tively spliced mRNA species of HCMV originate primarily, but not exclusively, from the IE gene regions. Some of the alternatively spliced variants of the IE region of HCMV have been investigated (14, 15) . Recently, new evidence of mRNA splicing was obtained from the RL8A, UL74A, UL124 and UL150A genes (16) . Alternatively, spliced mRNAs encode a number of gene products with different sizes (16) . Rawlinson and Barrell (18) found a new spliced transcript and an unspliced transcript, which were named UL21.5 (9, 10, 17) , from the complementary strand of the predicted UL21A gene of the HCMV AD169 genome during the late infection phase. UL21.5 was found to be one of the viral transcripts packaged within HCMV particles (17) . The virion-associated UL21.5 mRNA is translated into a secreted glycoprotein, which is a viral chemokine decoy receptor specifically interacting with RANTES (19) .
A spliced transcript that is highly homologous with the UL21.5 transcript was previously detected from a late HCMV cDNA library in our laboratory (20) . In the present study, four novel low-abundance spliced transcripts, termed UL21.5 multiple spliced transcripts (UL21.5 MST), were identified to be transcribed from the UL21.5 gene region of a low-passage strain dependent upon different combinations of three splice donor sites and three splice acceptor sites. Furthermore, the splice donor and acceptor sites were validated by an in vitro transcriptional system. The necessary regulatory sequences of one splice donor site and two splice acceptor sites were also identified.
Validation of three splice donor and three splice acceptor sites for regulating four novel low-abundance spliced transcripts of human cytomegalovirus UL21.5 gene locus
Materials and methods

Viruses, cells and specimens.
A low-passage HCMV strain H was isolated from a urine sample of a congenitally HCMV-infected infant at the Department of Pediatrics at the Affiliated Shengjing Hospital of China Medical University, Shenyang, China. MRC-5 and HEK293 cells were obtained from Shanghai Institute of Cell Biology and Biochemistry (Shanghai, China). The H strain was inoculated into MRC-5 cells maintained in minimal essential medium (MEM) supplemented with 2% fetal calf serum (HyClone, Logan UT, USA) and penicillin-streptomycin in an incubator at 37˚C, 5% CO 2 . For HCMV IE infection, the cells were harvested at 24 h post-infection (hpi) in the presence of 100 µl/ml of the protein synthesis inhibitor, cycloheximide (Sigma, St. Louis, MO, USA). For E infection, 100 µl/ml of the DNA synthesis inhibitor, phosphonoacetic acid (Sigma), were added to the medium immediately following inoculation, and the infected cells were harvested at 48 hpi. For L infection, the cells were harvested at 72 hpi without any drug treatment. HEK 293 cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (HyClone) and penicillin-streptomycin at 37˚C in 5% CO 2 .
R NA preparation. Tot a l R NA was isolated from HCMV H-infected and uninfected MRC-5 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). To remove contaminating DNA, the extracted RNA was treated with DNA-free reagent (Ambion, Austin, TX, USA). The quantity and purity of the RNA preparations were estimated by optical density value detection.
cDNA library screening. A full-length cDNA library of the HCMV H strain was previously constructed using the pBluescript Ⅱ SK vector (20) . Recombinants of the cDNA library were transferred into the E. coli JM109 strain (Promega, Madison, WI, USA). A total of 8,600 cDNA clones were randomly selected and inoculated into LB medium. A pair of specific primers for the UL21.5 gene region (R-s3 and 5'R3) (Table I and Fig. 1 ) were designed and used to screen UL21.5 genespecific clones from the cDNA library by graded polymerase chain reaction (PCR) as described in previous studies (21, 22) . The PCR reaction conditions were as follows: 95˚C for 5 min, 30 cycles of 95˚C for 45 sec, 56˚C for 45 sec and 72˚C for 30 sec, followed by a final elongation at 72˚C for 10 min. Inserts of the selected clones were sequenced using the vector primers, M13F and M13R, on an ABI PRISM 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA). The screening results allowed us to obtain cDNA clones containing sequences between the screening primers from both genome strands.
Northern blot analysis. Northern blot analysis was performed using the digoxigenin (DIG) system (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. Initially, the same amount of IE, E and L RNA preparations of the HCMV H strain and RNA from uninfected MRC-5 cells (10 µg RNAs in each lane for detection by probe 1, and 5 µg RNA in each lane for detection by probe 2 and UL99 probe) were subjected to denaturing agarose gel [1.5% (wt/vol)] electrophoresis in the presence of formaldehyde along with the DIG-labeled RNA molecular weight marker I (Roche Diagnostics). The probes were synthesized and labeled using a DIG Northern Starter kit (Roche Diagnostics) and primers 21.5-NS1 and 21.5-NAS1, 21.5-NS2 and 21.5-NAS2, as well as 99-NS and 99-NAS. The primers were designed according to the sequences of the transcripts identified by cDNA library screening, the UL21.5 transcript reported above (Table I and Fig. 1 ) and the UL99 gene of the HCMV Towne strain (GenBank accession no: FJ616285.1). A probe located from nt 27537 to 27323 complementary to the antisense strand of the UL21.5 gene locus was synthesized. The separated RNA was transferred onto a positively charged nylon membrane by capillary transfer. Subsequently, the nylon membrane was baked at 80˚C for 2 h followed by pre-hybridization at 65˚C for 30 min using DIG Easy Hyb buffer and hybridization to the UL21.5 and UL99 probes at 65˚C for 16 h. The hybridized probes were reacted to the anti-DIG conjugated to alkaline phosphatase and the chemiluminescence substrate CDP-Star, and were exposed using ChemiDoc™ XRS+ (Bio-Rad Laboratories, Hercules, CA, USA). To ensure that equal amounts of RNA were loaded in each experiment, the RNA preparations were adjusted by comparing them to the quantities of the 28S and 18S rRNA in the same RNA preparations, which were estimated by electrophoresis and ethidium bromide staining.
Reverse transcription PCR (RT-PCR).
According to the results of cDNA library screening, a set of primers, flanking the introns of the spliced transcripts identified, were designed. RT-PCR was performed using an RNA PCR kit (AMV) version 3.0 (Takara Biotechnology, Dalian, China). First-strand cDNA was synthesized with an oligo(dT) primer at 42˚C for 30 min, 95˚C for 5 min, 5˚C for 5 min using L RNA from the HCMV H-infected MRC-5 cells. Subsequently, hot-start nested PCR was performed using two pairs of primers, R-s1 and R-a1, as well as R-s2 and R-a2 for identification of the spliced transcripts, and using primers R-s3 and 5'R3, as well as R-s3 and 5'R4 for the identification of the UL21.5 transcripts (Table I and Fig. 1 ). All the reactions were carried out at 94˚C for 3 min, 30 cycles of 94˚C for 30 sec, 56˚C for 30 sec, and 72˚C for 2 min, and a final extension at 72˚C for 10 min. A negative control reaction by omitting the reverse transcription step was carried out concurrently.
Rapid amplification of cDNA ends (RACE).
To determine the 3' and 5' ends of the UL21.5 transcripts, RACE was performed using the 3'-full RACE Core Set version 2.0 and 5'-full RACE kits (Takara Biotechnology) according to the manufacturer's instructions. Using L RNA preparations from the HCMV H-infected MRC5 cells, first-strand cDNA was synthesized with M-MLV reverse transcriptase using oligo(dT)-adaptor primer (3'RACE) and random 9-mer Primer (5'RACE) provided by the respective kits. In the 5'RACE experiments, reactions without tobacco acid pyrophosphatase (TAP) and M-MLV, which exclude the interference caused by the 5'-terminal phosphate of tRNA, rRNA and incomplete mRNA and exclude the interference caused by DNA pollution, were performed as two control reactions. Subsequently, specific sequences of the first-strand cDNA were amplified by PCR using the specific primers, 3'F1 and 3'F2 for 3'RACE, and the primers, 5'R1 and 5'R2, as well as 5'R3 and 5'R4, for 5'RACE. The primers are listed in Table I and shown in Fig. 1 .
Plasmid construction.
To construct an expression vector for the UL21.5 gene, the sequence containing all the introns of the HCMV UL21.5 gene region from nt 25276 to 27421 was amplified by PCR using H strain DNA as a template and a pair of primers, M-S and M-AS, which introduce a SalI and NotI recognition site into the ends of the amplicon respectively (Table I ). The PCR products were digested using SalI and NotI, and then cloned into the SalI and NotI sites of the pCMV-HA vector, resulting in the plasmid, pCMV-UL21.5 MST (Table II) .
To identify the determinant regulatory region of the splice sites found in this study, recombinant vectors carrying mutant sequences adjacent to one splice donor site (D1 at nt 25533) and two splice acceptor sites (A1 at nt 26597 and A2 at nt 26633) were generated using specific primers containing mutant sequences.
To generate an expression vector with a mutant sequence around the splice donor site D1, a 9-bp sequence from nt 25531 to nt 25539 was mutated from GCGGTGAGT to TGAGGGTTG. First, one 264-bp SalI-BglII fragment and one 1882-bp BglIINotI fragment were amplified using two pairs of primers, M-S Normal fonts represent gene-specific sequences, italic fonts represent mutant sequences. Sequences underlined are recognition sites of the restriction enzymes, SalI (GTCGAC), NotI (GCGGCCGC) and BgIII (AGATCT). Sequence positions shown refer to those of the Towne strain (GenBank accession no: FJ616285.1).
and M-d-as, as well as M-dL-s and M-AS. Following digestion with SalI and BglII, as well as BglII and NotI, the fragments were inserted into the pCMV-HA vector at the SalI and NotI sites, resulting in pCMV-UL21.5-mut-D1 (Table II) .
To construct an expression vector with a mutant sequence adjacent to the splice acceptor site A1 at nt 26597, a 20-bp sequence located upstream of the A1 site from nt 26577 to nt 6596 was mutated from GGATTGGGTAGGGGTTGCAG to GATCTGATGTTTTGAGGGTT. Using two pairs of primers, M-S and M-a1-as, as well as M-a1L-s and M-AS, one 1,321-bp SalI-BglII fragment and one 825-bp BglII-NotI fragment were obtained. Following digestion with SalI and BglII, as well as BglII and NotI, the fragments were cloned into the SalI and NotI sites of the pCMV-HA vector, resulting in pCMV-UL21.5-mut-A1 (Table II) .
To generate an expression vector containing a mutant sequence around the splice acceptor site A2 at nt 26633, a series of expression vectors, pCMV-UL21.5-mut-A2-1 containing a 20-bp mutant sequence located upstream of the A2 site from nt 26613 to nt 26632, pCMV-UL21.5-mut-A2-2 containing a 20-bp mutant sequence around the A2 site from nt 26621 to nt 26640 and pCMV-UL21.5-mut-A2-3 containing a mutant sequence from nt 26621 to nt 26650 were generated using a method similar to the one described above. In pCMV-UL21.5-mut-A2-3, a 30-bp sequence adjacent to the splice acceptor site A2 was mutated from CTCACCGACCAGCACACGG CGCTGTTCTGG to GATCTGGATGGTGGTGATGTTTT GAGGGTT (Table II) . The inserts of the plasmids constructed above were confirmed by sequencing.
Transfection of HEK 293 cells and detection of transcripts by RT-PCR.
The HEK 293 cells were plated onto 6-well plates at a density of 2x10 5 cells/well. Twenty-four hours later, the cells were transfected with 4 µg of each plasmid DNA (pCMV-UL21.5 MST, pCMV-UL21.5-mut-D1, pCMV-UL21.5-mut-A1, pCMV-UL21.5-mut-A2-1, pCMV-UL21.5-mut-A2-2 and pCMV-UL21.5-mut-A2-3) using 10 µl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) diluted in serum-free medium as recommended by the manufacturer. The cells were harvested 48 h after transfection, and the RNA of the transfected cells was prepared as described above. Subsequently, RT-PCR was performed using the RNA preparations and one pair of primers, R-s2 and R-a2. The total RNA isolated from the HEK 293 cells and the pCMV-HA-transfected HEK 293 cells was used as the controls. An RT-PCR reaction without M-MLV in the reverse transcription step was performed concurrently.
Cloning and sequencing. All the RACE and RT-PCR products were gel-purified and cloned into the vector, PCR2.1 (Invitrogen). Subsequently, the inserts of the identified clones were sequenced on the ABI PRISM 3730 DNA analyzer (Applied Biosystems). The nucleotide positions referred to in the present study are in reference to the sequence of the HCMV Towne strain (GenBank accession no: FJ616285.1).
Results
UL21.5 spliced transcripts obtained from the cDNA library.
By graded PCR screening, 34 cDNA clones were found to contain sequences congruent with the UL21.5 gene locus from 8,600 clones of the HCMV cDNA library. The sequencing results revealed that all 34 cDNA sequences terminated at nt 27543, which is downstream of a poly(A) signal (ATTAAA) at nt 27513-27518. Among the identified cDNA sequences, 25 sequences with lengths from 417 nt to 421 nt began at the region from nt 27040 to nt 27044, which are similar to the spliced UL21.5 transcript reported previously (18) . Five sequences with lengths from 765 nt to 1386 nt began from nt 26696 to 26082, which have a similar structure as transcript I (Fig. 1) . The sequence with its 5' end at nt 24889 comprised three exons and two introns (Fig. 1, transcript III) , and was 1473 nt in length.
However, no clone containing an unspliced UL21.5 sequence or a sequence from the antisense strand of the UL21.5 gene was obtained from the cDNA library.
UL21.5 transcripts identified by northern blot analysis.
To analyze potential transcripts arising from the UL21.5 gene locus during HCMV infection, northern blot analyses were performed using RNA preparations from the MRC-5 cells infected with the HCMV H strain at the IE, E and L phases and RNA from mock-infected cells. Three clusters of low-abundance transcripts with lengths of ~1250 nt, ~1517 nt and 1900-2100 nt were detected in the L RNA preparation by the UL21.5-specific probe 1, which is located at nt 26785-27069 (Fig. 2, lane 8) . A cluster of an abundant transcript ~400-600 bp was detected in the same L RNA by the UL21.5-specific probe 2, which was located at nt 27323 to 27537 (Fig. 2, lane 12) . No specific band to any of the UL21.5 probes was observed in the IE, E or mock-infected RNA preparations (Fig. 2, lanes 5-7 and 9-11) . A specific band to the UL99 probe, which is a true late phase gene (23) , was detected in the L RNA preparation but not in the IE and E RNA preparations (Fig. 2, lanes 1-4) . No transcript was detected by the probe complementary to the antisense strand of the UL21.5 gene locus (data not shown).
UL21.5 multiple spliced transcripts confirmed by RT-PCR analyses.
To confirm the UL21.5 spliced transcripts obtained from the cDNA library and identify more spliced transcripts, RT-PCR was performed using L RNA preparations of the HCMV H strain. The sequencing results revealed that, apart from the UL21.5 transcripts (Fig. 3B) , four spliced transcripts (Fig. 1 , transcripts I to IV) were transcribed from the UL21.5 transcription region (Fig. 3A) mediated by different combinations of three splice donor sites and three splice acceptor sites (Fig. 1 Spliced transcripts undetected in the in vitro expression system by the primers, R-s2 and R-a2. b Positions of the splice donor and acceptor sites. Transcripts II and III are related to acceptor site A1, transcript IV is related to acceptor site A2, and transcripts III and IV are related to donor site D1.
and Table III ). The UL21.5 gene locus consisted of six exons and four introns (Fig. 1) . The largest intron is intron 4, which is located between the splice donor site D1 at nt 25533 and the splice acceptor site A2 at nt 26633, with a length of 1099 nt. The shortest intron is intron 1 which is located between the splice donor site D3 at nt 27151 and the splice acceptor site A3 at nt 27235, with a length of 83 nt. Alterable combinations of the six exons constitute the four spliced transcripts (Fig. 1) .
3' and 5' ends of UL21.5 multiple spliced transcripts mapped by RACE.
To further map the 3' and 5' ends of the UL21.5 multiple spliced transcripts (UL21.5MST), RACE experi- 
transcripts. Total cellular RNA prepared from uninfected cells (Mock) and HCMV-[at a multiplicity of infection (MOI) of 2] infected cells at the immediate-early (IE), early (E) and late (L) infection phases
were examined by northern blot analysis using HCMV UL21.5-specific probe 1 (located at nt 26785-27069) and probe 2 (located at nt 27323 to 27537) and UL99-specific probe, respectively. Equivalent amounts of RNA, 10 µg in lanes 5-8 and 5 µg in lanes 1-4 and 9-12, were subjected to agarose gel electrophoresis in each experiment. Quantities of 28S and 18S rRNA in the RNA preparations were estimated by electrophoresis and ethidium bromide staining. Positions of molecular size markers (03-6.9 kb) are noted at the right side. Black arrows point to the specific bands. Figure 3 . Results of RT-PCR for UL21.5 transcripts. RT-PCR was performed using the late-phase (L) RNA of the H strain (HL) and two pairs of primers, R-s1 and R-a1, as well as R-s2 and R-a2, which were located upstream of the splice donor site D1 at nt 25533 and downstream of the splice acceptor site A2 at nt 26633 (A), and the primers, R-s3 and 5'R3, as well as R-s3 and 5'R4, which span the intron 1 (B). Based on sequencing results, RT-PCR products of the UL21.5 spliced transcripts are indicated by arrows with corresponding names. The products of transcripts I, II, III and IV were amplified by RT-PCR using the primers, R-s1 and R-a1, as well as R-s2 and R-a2 and were 1402, 1114, 338 and 302 bp in length, respectively. Those of the UL21.5 transcript were 188 bp (spliced) and 272 bp (unspliced). To exclude the possibility of DNA contamination, a reverse reaction without reverse transcriptase M-MLV (MLV-) was used as a negative control. ments were performed using the L RNA of the HCMV H strain. The sequencing result of the 3'RACE product (Fig. 4A) identified a 3' end at nt 27543 downstream of the poly(A) signal (ATTAAA) at nt 27513-27518, which is consistent with that of the transcripts identified by cDNA library screening.
In 5'RACE experiments, two specific products were obtained using 5'R1 and 5'R2 (nested) primers (Table I and (Table IV) . Among these, the transcript lengths with the possible 5' ends at nt 24835 and nt 24895, and the possible structures of transcripts III and IV were 1470-1566 nt, which may correspond to the ~1517 nt transcripts found in northern blot analysis. By contrast, the lengths of transcripts with the possible 5' ends at nt 25220 and nt 25244 and the possible structures of transcripts III and IV were 1121-1179 nt, which may correspond to the ~1250 nt transcripts, and those with the possible 5' ends at nt 25220 and nt 25244, and the possible structures of transcript II were 1946-1968 nt, which may correspond to the 1900-2100 nt transcripts identified in northern blot analysis. Four ORFs were predicted in the spliced transcripts identified (Table IV) . As the ORF predicted in the UL21.5 spliced transcript, ORF A (from nt 27069 to nt 27151 and from nt 27235 to nt 27466), ORF B (from nt 26845 to nt 27093) and ORF C (from nt 26651 to nt 26929) were exactly the same in transcripts II, III and IV. And ORF D, E and F were specific for transcripts II, III and IV, respectively.
In order to confirm the 5' ends located from nt 27040 to 27044, which were obtained in the cDNA library screening, two other nested primers, 5'R3 and 5'R4 (Table I and Fig. 1 ), were used in 5'RACE. One ~300-bp product was obtained (Fig. 4C) . The sequencing results of this product showed three possible 5' ends located at nt 27040, 27041 and 27043, respectively; this was in accordance with the results of cDNA library screening.
Determinant regulatory region for a splice donor site and two splice acceptor sites identified by an in vitro expression system. To confirm that the UL21.5 MST was derived from splice events, the plasmid, pCMV-UL21.5 MST, was constructed. As shown in lane 8 of Fig. 5 , in accordance with those identified by RT-PCR using the primers, R-s2 and R-a2, four spliced transcripts were confirmed by the sequencing results of the bands.
To identify the determinant regulatory regions necessary for splice sites D1 (at nt 25533), A1 (at nt 26597) and A2 (at nt 26633) (Fig. 1) in the UL21.5 gene locus, expression vectors containing mutant sequences around the splice donor site D1 and adjacent to the splice acceptor sites A1 and A2 were constructed (Table II) . RT-PCR analyses were performed using RNA preparations from the HEK 293 cells trans- Table III . Splicing patterns of UL21.5 MST mapped in the study.
Related donor
Related acceptor A1-A3 and D1-D3 represent the names of splice acceptor and donor sites, respectively. Normal fonts represent exon sequences, and italic fonts represent the intron sequences. The positions of the donor and acceptor sites refer to the sequence of the Towne strain (GenBank accession no: FJ616285.1). Nucleotides for the formation of the splicing patterns are underlined.
fected with pCMV-UL21.5-mut-D1, pCMV-UL21.5-mut-A1, pCMV-UL21.5-mut-A2-1, pCMV-UL21.5-mut-A2-2 and pCMV-UL21.5-mut-A2-3, and one pair of primers, R-s2 and R-a3. The sequencing results of the RT-PCR products revealed that transcripts III and IV, which are relevant to the splice donor site D1, were not obtained from the HEK 293 cells transfected with pCMV-UL21.5-mut-D1 (Fig. 5 , lane 2 and Table II) due to a 9-bp sequence mutation from nt 25531 to nt 25539 around the splice donor site D1. However, transcripts II and III, which are relevant to the splice site A1, were not detected in the HEK 293 cells transfected with pCMV-UL21.5-mut-A1 (Fig. 5 , lane 6 and Table II) Table II) , which is relevant to the splice acceptor site A2, due to a further 10-bp fragment mutation of GCTGTTCTGG from nt 26641 to 26650, compared to the pCMV-UL21.5-mut-A2-2.
Discussion
It has been previously believed that HCMV mRNA splicing is restricted to a relatively small IE region of the HCMV genome (24), until a group of spliced L genes were Table IV . Analyses of the UL21.5 multiple spliced transcripts based on RACE.
Transcripts with possible 5' ends and structures The products corresponding to the transcripts shown in Fig. 1 are marked by each transcript's name. RT-PCR analyses followed by sequencing were performed on first-strand cDNA using the primers, R-s2 and R-a2. The products of transcripts I, II, III and IV were 1402, 1114, 338 and 302 bp in this amplification system. described (18) . The UL21.5 transcript, which consists of a spliced and a non-spliced transcript, was first reported by Rawlinson and Barrell (18) and later re-termed by Bresnahan and Shenk (17) . The UL21.5 transcript is an important HCMV virion RNA for the virus replication cycle (25). Together with the HCMV virion, the UL21.5 transcript is delivered into the infected cell and is translated to a secreted glycoprotein, which functions as a viral chemokine decoy receptor specifically interacting with the RANTES chemokine (17, 19) . It is also possible that virion-RNA plays a structural role in the HCMV assembly.
In the present study, transcripts from the HCMV UL21.5 region were further analyzed using a low passage HCMV strain. Apart from the higher abundant UL21.5 transcripts reported, three clusters of low-abundance transcripts were detected by probe 1 in L RNAs in northern blot experiments. Four spliced transcripts with a 3' co-terminus at nt 27543 of the UL21.5 gene locus were identified by cDNA library screening, RACE and RT-PCR. One ORF, which was the same as that predicted in the UL21.5 spliced transcript, was predicted in all possible forms of the low-abundance spliced transcripts II, III and IV. Apart from this ORF, three transcript-specific ORFs were predicted in the low-abundance spliced transcripts II, III and IV, respectively (Table IV) .
In general, three classes of transcripts are expressed from a genome, including high-, intermediate-and low-abundance transcripts (26) . Although the majority of the high-and intermediate-abundance transcripts have been identified, it remains a serious challenge to identify the low-abundance transcripts (27, 28) . To date, some low-abundance transcripts have been identified in HCMV. As a low-abundance spliced transcript from the IE gene region, the IE18 transcript was previously detected in infected human monocyte-derived macrophages at the IE phase, but was not detectable during normal infection (29) . The authors concluded that the IE18 transcript exhibits cell type-specific expression indicating differential regulation of the major IE gene region in different permissive cell types (29) . By detection in peripheral blood mononuclear cells of organ transplant recipients with different viral DNA loads, the natural killer (NK) cell decoy gene, UL18, was demonstrated to be produced through a low-abundance transcript late during the infectious cycle at a time coincidental with the increased risk of NK cell lysis (30) . It can be hypothesized that the existence of the lowabundance UL21.5 spliced transcripts in the HCMV genome may also play some unknown role during HCMV infection.
Little was known about splicing situations in HCMV until deep sequencing was used to bring high resolution to the HCMV transcriptome (16) . Multiple spliced transcripts have been found in UL37, UL73, UL111A, UL122, UL123, UL128 and US3 to date (14, 15, 29, (31) (32) (33) (34) (35) (36) (37) (38) (39) . In the present study, four previously unrecognized spliced transcripts were identified. Based on the structures of UL21.5 MST identified in this study and the findings of Rawlinson and Barrell (18) , three splice donor sites and three splice acceptor sites were proposed in the UL21.5 gene locus. According to the structures of the four introns indentified in UL21.5 MST, the splicing pattern is a canonical pattern of GT-AG.
Three signals are known to direct splicing events, including the 5' splice site (5'ss) at the 5' end of the intron, the polypyrimidine tract/3' splice site (PPT-3'ss) at the 3' end of the intron and a branch site (BS) upstream of the PPT-3'ss (40) (41) (42) (43) . According to previous studies (40, 41) , the 5' element generally is located in the position -3 to +6 (the third position upstream the 5'ss and the sixth position downstream the 5'ss, respectively), and the essential 3' element is generally located at nt -3 to -12 upstream of the 3'ss (44) (45) . To further validate these canonical splice sites and find the determinant regulatory region necessary for splicing events, an in vitro system was used in the present study. Based on the above principles, the expression plasmid, pCMV-UL21.5 MST, and plasmids containing mutant 5' element or 3' element of the UL21.5 MST coding sequences were constructed and used in this system. Similar to those found in HCMV H-infected MRC5 cells, four spliced transcripts were identified from HEK 293 cells transfected with the plasmid, pCMV-UL21.5 MST. This finding confirmed that the splicing events occurred during transcription. However, when mutation occurred adjacent to the splice donor site D1 at nt 25533 (in plasmid pCMV-UL21.5-mut-D1), D1-related transcripts (transcripts III and IV) of UL21.5 MST were not detected from the transfected cells. This result indicated that the 9-bp sequence around D1 from nt 25531 to nt 25539, which is exactly in the 5' element, is necessary for the activity of the splice donor site D1. Similarly, the 20-bp sequence just upstream of the splice site A1 at nt 26597 from nt 26577 to nt 26596, which includes the 3' element, is important for splice acceptor site A1, as mutation in this region resulted in the loss of A1-related transcripts (transcripts II and III). However, the determinant regulatory region that is necessary for activity of splice acceptor site A2 at nt 26633 is located not in the 3' element but in the sequence from nt 26641 to nt 26650, as the plasmid containing a mutant sequence in this region (pCMV-UL21.5-mut-A2-3) led to the loss of A2-related transcripts (transcript IV).
Overall, in addition to the UL21.5 transcript, four novel low-abundance 3'-coterminal spliced transcripts were identified to transcribe from the UL21.5 gene locus during late-phase infection. Three splice donor sites and three splice acceptor sites found in this region were validated to be functional splice sites by an in vitro expression system. Determinant regulatory regions of one splice donor site and two splice acceptor sites were identified in corresponding regions by mutation experiments. Alteration of the donor or acceptor splice sites may result in the loss of their related transcripts.
